CN102977105A - Synthesis method of 3(methyl),7-diazabicyclooctane - Google Patents

Synthesis method of 3(methyl),7-diazabicyclooctane Download PDF

Info

Publication number
CN102977105A
CN102977105A CN2012105000348A CN201210500034A CN102977105A CN 102977105 A CN102977105 A CN 102977105A CN 2012105000348 A CN2012105000348 A CN 2012105000348A CN 201210500034 A CN201210500034 A CN 201210500034A CN 102977105 A CN102977105 A CN 102977105A
Authority
CN
China
Prior art keywords
methyl
limited
degree
aluminium hydride
lithium aluminium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012105000348A
Other languages
Chinese (zh)
Inventor
张福治
丁炬平
张仁延
余强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cgenetech Suzhou China Co Ltd
Original Assignee
Cgenetech Suzhou China Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cgenetech Suzhou China Co Ltd filed Critical Cgenetech Suzhou China Co Ltd
Priority to CN2012105000348A priority Critical patent/CN102977105A/en
Publication of CN102977105A publication Critical patent/CN102977105A/en
Pending legal-status Critical Current

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention discloses a synthesis method of 3(methyl),7-diazabicyclooctane. Aiming at the defects that the traditional synthesis method of 3(methyl),7-diazabicyclooctane has low reaction yield, requires strict conditions and does not easily realize purification, the invention proposes a way of performing addition ring closing between 1-methylpyrrole-2,5-diketone serving as a start raw material and nitromethoxymethylbenzyltrimethylsiliconmethylammonia and reducing with lithium aluminum hydride and finally performing debenzylation to obtain 3(methyl),7-diazabicyclooctane. According to the synthesis method disclosed by the invention, the whole process has high yield and is easy to operate, the product is easy to purify, and column chromatography is avoided; and the method is suitable for industrialization, and the cost of raw materials is greatly reduced.

Description

3 (methyl), 7-diazabicyclo octane synthetic
Technical field
The present invention relates to the 3(methyl), synthesizing of 7-diazabicyclo octane also relates to the synthetic of its intermediate and uses, and belongs to medical, chemical technology field.
Background technology
The 3(methyl), 7-diazabicyclo octane is important chemistry, chemical intermediate, be widely used in medicine and pesticide field, especially aspect antitumor and similar rheumatism new drug synthetic, be seen at present the analogue synthetic route of report seldom, and severe reaction conditions mostly, yield is low, is difficult for purifying, is difficult to industrialization.
Summary of the invention
The present invention is directed to the 3(methyl), 7-diazabicyclo octane synthetic method reaction yield in the past is low, condition is harsh, the deficiency that is difficult for purifying, invented described with 1-methylpyrrole-2, the 5-diketone is that ring is closed in starting raw material and the addition of n-formyl sarcolysine oxygen methyl-benzyl trimethyl silicane methyl ammonia, reduce last debenzylation with Lithium Aluminium Hydride again and obtain the 3(methyl), the route of 7-diazabicyclo octane makes whole process yield high, easy handling, the good purifying of product, avoid column chromatography, be fit to industrialization, raw materials cost reduces greatly.
Described 3(methyl), 7-diazabicyclo octane is synthetic, by 1-methylpyrrole-2, the 5-diketone is that starting raw material becomes (3) catalyst system therefor including but not limited to trifluoroacetic acid with n-formyl sarcolysine oxygen methyl-benzyl trimethyl silicane methyl ammonia addition pass cyclization, tosic acid, sulfuric acid, methylsulfonic acid etc., first-selected trifluoroacetic acid, solvent is including but not limited to tetrahydrofuran (THF), dioxane, methylene dichloride, ethylene dichloride etc., first-selected methylene dichloride, temperature of reaction is not limited to zero degree to 50 degree, first-selected 25 degree, and the time was not limited to 0.5 hour to 48 hours.
Described 3(methyl), 7-diazabicyclo octane is synthetic, revert to (4) reduction reagent including but not limited to Lithium Aluminium Hydride by intermediate (3), borine dimethyl sulphide, sodium borohydride/aluminum chloride, first-selected Lithium Aluminium Hydride, temperature of reaction is not limited to 25 degree to 100 degree, first-selected 65 degree, and the time is not limited to half an hour to 72 hour, first-selected 24 hours, wherein aftertreatment destruction Lithium Aluminium Hydride method was the saturated sodium pyrosulfate aqueous solution.
Above-mentioned with 1-methylpyrrole-2, the 5-diketone is that the chemical reaction route of starting raw material is as follows:
Figure 53599DEST_PATH_IMAGE001
Embodiment
Embodiment:
Preparation compound (3):
Starting raw material 1-methylpyrrole-2,5-diketone 222 grams (2.0 moles) are dissolved in 2.5 liters of methylene dichloride, add n-formyl sarcolysine oxygen methyl-benzyl trimethyl silicane methyl ammonia 522.3 grams (2.2 moles), 5 milliliters of trifluoroacetic acids (catalytic amount), add rear room temperature reaction 24 hours, reaction solution is transferred PH to 11, layering with the sodium hydroxide of 1N, the organic phase washing, the saturated salt washing, anhydrous sodium sulfate drying filters, be spin-dried for, re-crystallizing in ethyl acetate obtains beige solid 327.3 grams (yield 67%).
Preparation compound (4):
Compound (3) 244.3 grams (1.0 moles) that the upper step makes are dissolved in 2.5 liters of anhydrous tetrahydro furans, add Lithium Aluminium Hydride 159.6 grams (4.2 moles) in batches, add rear temperature rising reflux reaction 24 hours, be cooled to subzero 10 degree, the saturated sodium bisulfate about 1 of temperature control dropping is raised to does not have γ-ray emission, continues to stir 1 hour, filter, the tetrahydrofuran (THF) washing, anhydrous sodium sulfate drying is spin-dried for after the filtration and obtains oily matter 181.4 grams (yield 84%).
Preparation compound (5) is the 3(methyl), 7-diazabicyclo octane:
Compound (4) 108 grams (0.5 mole) that the upper step makes are dissolved in 1 liter of methyl alcohol, palladium carbon 10 grams of adding 10%, with reaction 48 hours under 2 atmospheric hydrogen environments 60 degree temperature behind the hydrogen exchange 3 times, cooled and filtered, methyl alcohol is washed, obtain yellow oil crude product 63 grams after being spin-dried for, dissolving crude product is in hydrogenchloride/methyl alcohol of 500 milliliters of 2N, stirred salify 1 hour, a large amount of solids are separated out, and filter and obtain pure product hydrochloride, and hydrochloride extracts after dissociating with the sodium hydroxide of 1N is molten, be spin-dried for and obtain pure 3(methyl), 7-diazabicyclo octane 47 grams (yield 74.6%).

Claims (3)

1. described with 1-methylpyrrole-2, the 5-diketone is that ring is closed in starting raw material and the addition of n-formyl sarcolysine oxygen methyl-benzyl trimethyl silicane methyl ammonia, reduce last debenzylation with Lithium Aluminium Hydride again and obtain the 3(methyl), the route of 7-diazabicyclo octane makes whole process yield high, easy handling, the good purifying of product, avoid column chromatography, be fit to industrialization, raw materials cost reduces greatly.
2. described 3(methyl), 7-diazabicyclo octane is synthetic, by 1-methylpyrrole-2, the 5-diketone is that starting raw material becomes (3) catalyst system therefor including but not limited to trifluoroacetic acid with n-formyl sarcolysine oxygen methyl-benzyl trimethyl silicane methyl ammonia addition pass cyclization, tosic acid, sulfuric acid, methylsulfonic acid etc., first-selected trifluoroacetic acid, solvent is including but not limited to tetrahydrofuran (THF), dioxane, methylene dichloride, ethylene dichloride etc., first-selected methylene dichloride, temperature of reaction is not limited to zero degree to 50 degree, first-selected 25 degree, and the time was not limited to 0.5 hour to 48 hours.
3. described 3(methyl), 7-diazabicyclo octane is synthetic, revert to (4) reduction reagent including but not limited to Lithium Aluminium Hydride by intermediate (3), borine dimethyl sulphide, sodium borohydride/aluminum chloride, first-selected Lithium Aluminium Hydride, temperature of reaction is not limited to 25 degree to 100 degree, first-selected 65 degree, and the time is not limited to half an hour to 72 hour, first-selected 24 hours, wherein aftertreatment destruction Lithium Aluminium Hydride method was the saturated sodium pyrosulfate aqueous solution.
CN2012105000348A 2012-11-30 2012-11-30 Synthesis method of 3(methyl),7-diazabicyclooctane Pending CN102977105A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012105000348A CN102977105A (en) 2012-11-30 2012-11-30 Synthesis method of 3(methyl),7-diazabicyclooctane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012105000348A CN102977105A (en) 2012-11-30 2012-11-30 Synthesis method of 3(methyl),7-diazabicyclooctane

Publications (1)

Publication Number Publication Date
CN102977105A true CN102977105A (en) 2013-03-20

Family

ID=47851496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012105000348A Pending CN102977105A (en) 2012-11-30 2012-11-30 Synthesis method of 3(methyl),7-diazabicyclooctane

Country Status (1)

Country Link
CN (1) CN102977105A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016078108A1 (en) * 2014-11-19 2016-05-26 苏州乔纳森新材料科技有限公司 Method for synthesizing 3-methyl-3,7-diazabicyclo[3.3.0]octane pharmaceutical intermediate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050234031A1 (en) * 2004-02-04 2005-10-20 Schrimpf Michael R Amino-substituted tricyclic derivatives and methods of use
CN101189233A (en) * 2003-09-19 2008-05-28 艾博特公司 Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acety lcholine receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189233A (en) * 2003-09-19 2008-05-28 艾博特公司 Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acety lcholine receptors
US20050234031A1 (en) * 2004-02-04 2005-10-20 Schrimpf Michael R Amino-substituted tricyclic derivatives and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016078108A1 (en) * 2014-11-19 2016-05-26 苏州乔纳森新材料科技有限公司 Method for synthesizing 3-methyl-3,7-diazabicyclo[3.3.0]octane pharmaceutical intermediate

Similar Documents

Publication Publication Date Title
CN103709121B (en) The preparation method of pharmaceutical grade 2-benzothiazolyl mercaptan and derivative DM thereof
CN102633686A (en) Preparation method of peramivir
CN102229613B (en) New process for synthesis of asenapine
CN102584795A (en) Preparing method of crizotinib
CN103030638B (en) Preparation method of (S, S)-8H-6H-pyrrolo [3, 4-b] pyridine
CN102850325A (en) Preparation method of Dabigatran etexilate key intermediate
CN103183673A (en) Synthesizing method of (S,S)-2,8-diazabicyclo[4.3.0]nonane
CN102391128A (en) Production method of antibiotic pharmaceutical intermediate mono-p-nitro benzyl malonate
CN104844593A (en) Synthetic method for Apixaban drug intermediate
CN102977105A (en) Synthesis method of 3(methyl),7-diazabicyclooctane
CN101215291B (en) Synthesis method of (+)-biotin and its derivatives
CN102321045B (en) Method for preparing high morphine hydrochloride
CN102603594B (en) Preparation method of (S)-oxiracetam
CN102010428A (en) Cefathiamidine compound and new preparation method thereof
CN102603595B (en) Preparation method of (S)-oxiracetam
CN103923135B (en) A kind of deuterated 5-hydroxyl color D-glucosamine glycoside derivates and preparation method thereof
CN101088999A (en) Process of synthesizing 3-amino quinine dihydrochloride
CN107955020B (en) Method for synthesizing benzimidazol oxazinone compound by copper salt catalysis in one pot
CN103664743B (en) The preparation method of (3S, 4R)-3-amido-4-methyl piperidine-1-carboxylic acid tert-butyl ester
CN112062705A (en) Synthesis method of 7-methyltryptophan
CN101486696B (en) Preparation of 2,5-dimethyl furan-3,4-dicarboxylic acid
CN101486694B (en) Preparation method of 2,5-dimethyl furan-3,4-dicarboxylate
CN102977104A (en) Synthesis of 2,4-dichloro-7-hydroxy-pyrrolo(2,3)pyrimidine
CN111187223B (en) Synthetic method of linagliptin intermediate 2-chloromethyl-4-methyl quinazoline
CN109776610A (en) Chiral P based on phenyl ethylamine skeleton, N, N ligand class compound and preparation method and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130320